Zito, C.; Manganaro, R.; Ciappina, G.; Spagnolo, C.C.; Racanelli, V.; Santarpia, M.; Silvestris, N.; Carerj, S.
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do. Cancers 2022, 14, 5403.
https://doi.org/10.3390/cancers14215403
AMA Style
Zito C, Manganaro R, Ciappina G, Spagnolo CC, Racanelli V, Santarpia M, Silvestris N, Carerj S.
Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do. Cancers. 2022; 14(21):5403.
https://doi.org/10.3390/cancers14215403
Chicago/Turabian Style
Zito, Concetta, Roberta Manganaro, Giuliana Ciappina, Calogera Claudia Spagnolo, Vito Racanelli, Mariacarmela Santarpia, Nicola Silvestris, and Scipione Carerj.
2022. "Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do" Cancers 14, no. 21: 5403.
https://doi.org/10.3390/cancers14215403
APA Style
Zito, C., Manganaro, R., Ciappina, G., Spagnolo, C. C., Racanelli, V., Santarpia, M., Silvestris, N., & Carerj, S.
(2022). Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do. Cancers, 14(21), 5403.
https://doi.org/10.3390/cancers14215403